Published online August 17, 2009
PEDIATRICS Vol. 124 No. 3 September 2009, pp. e484-e488 (doi:10.1542/peds.2009-0047)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Maranich, A. M.
Right arrow Articles by Rajnik, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maranich, A. M.
Right arrow Articles by Rajnik, M.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Varicella-Specific Immunoglobulin G Titers in Commercial Intravenous Immunoglobulin Preparations

MAJ Ashley M. Maranich, MDa,b and Lt Col Michael Rajnik, MDa

a Department of Pediatrics, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
b Department of Pediatrics, Walter Reed Army Medical Center, Washington, DC

BACKGROUND AND OBJECTIVES: Since the introduction of an effective vaccine in 1995, the incidence of primary varicella zoster virus (VZV) has greatly decreased. However, newborns and immunocompromised patients remain at risk for serious disease. Currently, varicella-specific immunoglobulin is recommended for treatment of nonimmune, exposed, high-risk patients with varicella-specific immunoglobulin. However, product inavailability has led to substitution of intravenous immunoglobulin (IVIg) for such prophylaxis on the basis of studies from the preimmunization era. No studies in the post–vaccine era have shown that IVIg contains adequate varicella-specific antibodies to protect patients at high risk. The overall effect of vaccination on varicella-specific immunoglobulin G (IgG) levels in donor-pooled IVIg products is unknown. We compared the varicella-specific IgG levels in prevaccine and current IVIg products.

METHODS: We used stored historic IVIg samples and current samples from our inpatient pharmacy. All samples were tested for varicella-specific IgG levels by enzyme-linked immunosorbent assay.

RESULTS: Ten historic lots and 24 current lots were tested. The overall mean value of varicella-specific IgG in the historic lots was 3.07 (SD: 0.70); the current lots had a mean of 3.83 (SD: 0.58). The postvaccine IVIg contained higher levels of antibody than the prevaccine lots.

CONCLUSIONS: We found that current IVIg preparations continue to have high levels of varicella-specific IgG despite the changing epidemiology of how immunity has been obtained. Given the results of this study, it is reasonable for physicians to comfortably substitute IVIg for varicella-specific immunoglobulin preparations when treating high-risk patients exposed to VZV.

Key Words: varicella zoster virus • intravenous immunoglobulin • vaccination

Abbreviations: VZV—varicella zoster virus • IVIg—intravenous immunoglobulin • IgG—immunoglobulin G • ISR—immune status ratio • ELISA—enzyme-linked immunosorbent assay

Accepted Apr 16, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?